Rewalk Robotics

Beleggen in aandelen beurs New York, Dow Jones index, Nasdaq-100 en S&P500
Plaats reactie
Munnybunny
Forum actieveling
Forum actieveling
Berichten: 935
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 386
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 11 Sep 2017 17:49

$1.85

En nu nog een PR en het kan nog hoger.


Munnybunny
Forum actieveling
Forum actieveling
Berichten: 935
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 386
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 14 Sep 2017 16:04

Nieuwe Duitse verzekeraar en een grote Amerikaanse verzekering zal mogelijks volgen.

Payer Coverage for ReWalk Expands in Germany with Barmer
PRNewswire FOLLOW
September 14, 2017 8:04am

Prominent German Insurer to Provide Exoskeleton Systems for All Qualifying Beneficiaries; Provides Update on U.S. Insurance Policy Coverage Reviews
MARLBOROUGH, Mass. and YOKNEAM ILIT, Israel, Sept. 14, 2017 /PRNewswire/ -- ReWalk Robotics Ltd. ("ReWalk" or the "Company")

RWLK 1.07%, today announced that one of the leading German insurers, Barmer, has signed a confirmation regarding the provision of ReWalk systems for all qualifying beneficiaries. This confirms the procurement of exoskeletons for users that meet the inclusion criteria and reach successful assessment by the German Medical Service of the Health Insurers (MDK) before and after training



"The continued expansion of data, the growing number of successful ReWalk users worldwide and the positive decision from the German Social Court have led Barmer to determine that exoskeletons are a standard of care for use in everyday life," said ReWalk CEO Larry Jasinski. "The progressive approach of a prominent Statutory Health Insurance group, such as Barmer, and an increase of purchases and expanded training efforts with the Workman's compensation BG (Berufsgenossenschaft) in Germany, marks meaningful progress to improve the quality of life for those with spinal cord injury."

Barmer has already begun processing claims with three beneficiaries entering training for in-home use of an exoskeleton. One of the most significant national insurers in Germany, and a member of the German Statutory Health Insurance network, Barmer provides insurance coverage for nearly 10 million people.

Separately, the Company announced that ReWalk continues to engage with U.S. national and regional insurance providers to secure potential coverage policies based on a growing wealth of data and a number of appeal rulings that have deemed exoskeleton devices a "medically necessary" standard of care for individuals with spinal cord injury (SCI). As part of this ongoing initiative, a large national insurance provider has requested additional information in order to continue to evaluate a change from their current non-coverage policy. The Company is also submitting data to two additional U.S. commercial groups for policy reviews.

Munnybunny
Forum actieveling
Forum actieveling
Berichten: 935
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 386
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 26 Sep 2017 12:49

Rewalk Robotics $15 mio share offering

The company says it will use net proceeds for "(i) sales, marketing and reimbursement expenses related to market development activities and broadening third-party payor coverage and (ii) research and development costs related to developing our lightweight 'soft suit' exoskeleton device aimed at assisting patients who have suffered a stroke."

Munnybunny
Forum actieveling
Forum actieveling
Berichten: 935
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 386
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 03 Okt 2017 13:07

Has a French firm finally achieved the holy grail of robotics? (And will that matter to customers?)

The biomechanics of bipedal walking are preposterously complex. A French firm claims to have built a robotic suit that can emulate the way we walk.


By Greg Nichols for Robotics | October 3, 2017 -- 09:19 GMT (10:19 BST)

Paris-based startup Wandercraft, which makes a signature robotic exoskeleton that allows wheelchair users to stand and walk, just announced a €15 million B round.

The founders plan to use the money to gain necessary certifications and bring what amounts to a stunning new version of an old idea to market. Wandercraft's unique offering? Its device actually replicates the biomechanical marvel of the human gait, which the company claims is a first for an exoskeleton.

But technological breakthroughs aren't always business successes.

Wandercraft's competitors include Ekso Bionics, ReWalk, and SuitX, among other manufacturers. All make devices that allow mobility-impaired persons to stand and walk. To date, the primary use for such devices is in rehab centers, where there's evidence they may help alleviate secondary complications associated with sitting in a wheelchair and can assist in rehabilitation from accident or stroke.

Will Wandercraft's advanced technology offer enough of an advantage to appeal to end users and rehab centers?

I had a chance to speak with founder and general manager Matthieu Masselin about his company's strategy as it enters a space that's seen more established companies struggle to achieve broad adoption. His answers provide a glimpse into how the technology is changing, as well as what the future may hold for current wheelchair users.

GN: You guys claim to be the first company to have figured out how to replicate the human gait. We've heard similar claims from others, notably Ekso Bionics and ReWalk. How is Wandercraft's exo different?

MM: We have a great respect for these pioneers. We have addressed the issue differently, starting by fully modeling how it to achieve a fully balanced, autonomous (e.g. without crutches) gait. Specifically, the exo walks without crutches and is self-balanced.

We use dynamic robotics, including algorithmic frameworks which are widely more complex to implement but able to create dynamic balance and are highly robust to perturbations. In particular, they handle motion as a dynamically controlled fall (hence 'dynamic') and not as a succession of static balance states.Typically, with some differences, Boston Dynamics uses the same sort of algorithms for Atlas.

GN: So you're actually replicating the biomechanics, the falling forward that makes walking so difficult to model and recreate?

MM: We deliver a truly bipedal walk compared to Ekso or ReWalk, which are actually offering quadrupedal walk -- the exo's two legs are completed with two other contact points. Nor is It like Rex [created by Rex Bionics] which is relying on static walking control strategies, i.e., allowing close to 0 acceleration and monitoring the center of mass of the system.

We implement strategies developed by the teams of Jessy Grizzle in Ann Harbor and Aaron Ames in Caltech for bipedal walk which have shown incredible robustness in real hardware and extreme likeness to human walk (see here for example). We collaborate closely with them, through publications such as this one and others we will disclose at the next ICRA conference.

These theories, generally referred to as HZD (for Hybrid Zero Dynamics) allow 3D walking on uneven terrain.

GN: Why go to all that trouble? Why replicate the human gait exactly?

MM: This is all for one purpose: getting rid of the crutches and achieving a device that will ensure system (exo + user) stability, rather than relying on the user for it. This is extremely important, as in the case of Rewalk or Ekso, physicians' feedback is that [the crutches] can hurt shoulders quite a lot and do not allow for effective treatment.

We really see ourselves as bringing the latest advances from humanoid robotics and dynamic walking to the first true use case of walking robots, which is rehab exoskeletons.

GN: What are the use cases for Wandercraft's exo? You mentioned wheelchairs. I'm curious if that's the primary market you're going after. Ekso Bionics, for example, started out going after wheelchair users but figured out there wasn't enough demand, so they broadened their approach. They've since pivoted to using their device to help stroke patients and spinal cord injury sufferers learn to walk again through gait training.

MM: We do focus on mobility impaired persons. It is a business and a cause. In the Northern Hemisphere, there are 3 to 5 million mobility impaired persons and 3000 large rehab centers that are immediately relevant to our technology. This is largely more than construction workers or military [two other current uses for exoskeletons].

The problem with unbalanced exos, using static robotics and requiring to walk on crutches, is twofold. First, treatments in healthcare centers is very limited because, one, gait is not realistic, and, two, walking with crutches puts a lot of strain on patients' shoulders and upper limbs. Thus you can't have frequent and intensive sessions.

Exos that are not self balanced offer no perspective for autonomous usage in activities of daily living. Which is our medium term goal.

GN: So further out you do see people using your technology in day-to-day life, and not just at rehab clinics?

MM: The potential synergy between autonomy and treatment is huge. This has been discussed in depth with many physical medicine physicians and physios.

We expect that the need for such exos is one order of magnitude higher than for unbalanced exos.

If you take France for instance. There are 357 rehab centers, 30 major ones (130+ beds). All have seen Ekso and ReWalk demos and only two have acquired their devices. The idea is great but the implementation is not satisfactory.

GN: So in the simplest terms, the model is ...

MM: Sell / lease clinical exos to healthcare centers in Europe by the end of 2018 and in the US by the end of 2019, offering better treatments. Then, "in some years," sell / lease personal exos to people for more autonomy in daily living.

GN: Take me through the technical specs of your suit.

MM: It runs on a typically core i7 with added processing power soon for more and different functions. Regarding batteries, today you get three to four hours of continuous usage, which allows one full day of typical rehab center work, also equivalent to one full day of urban usage. Dynamic robotics is extremely energy efficient as long phases of the gait cycle are not or little actuated.

The suit weighs more than 50kg, which is acceptable for rehab centers but will be slimmed for personal versions. But weight is not as critical as volume, since the exo carries itself.

GN: How much will units cost? And will they be available off the shelf or do they require customization?

MM: Cost is undisclosed to date. Rehab price will be comparable to comparable equipment.

The target personal version price is expected to be comparable to to-end powered wheelchairs--but we still have some work to do.

We expect to get CE Marking (European certification) in the second half of 2018 and the sell to European rehab centers.

http://www.zdnet.com/article/has-a-fren ... customers/

Munnybunny
Forum actieveling
Forum actieveling
Berichten: 935
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 386
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 17 Okt 2017 10:47

Soft Suit Exoskeleton Technology Begins Next Phase of Testing in Pre-Clinical Study

SOURCE ReWalk Robotics Ltd.

ReWalk Robotics & Harvard's Wyss Institute Are Collaborating on Design for Soft Exosuit for Stroke Survivors

YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., Oct. 16, 2017 /PRNewswire/ -- ReWalk Robotics Ltd. (Nasdaq: RWLK) ("ReWalk") today announced that the soft exosuit technology currently in development has entered the next phase of testing and verification in collaboration with researchers at Harvard University's Wyss Institute for Biologically Inspired Engineering. This phase of testing includes evaluating the ReWalk exosuit system that is based on Wyss Institute exosuit technology with individuals who have had a stroke, in preparation for upcoming clinical trials to be run at clinical sites in 2018.

This technology is designed for use by stroke survivors with lower limb disability. Soft exoskeleton technology, also called a soft exosuit, is being designed to serve a number of patient populations, including individuals with Multiple Sclerosis, Parkinson's Disease and other mobility challenges.

In 2016, ReWalk announced a collaboration with the Wyss Institute to support ongoing technology development and testing of lightweight exoskeleton system concepts and designs for lower limb disabilities and licensed intellectual property (IP) from Harvard University. The soft suit design transmits power to key joints of the legs with cable technologies and fabric-based designs; the soft suit is powered with software and mechanics that are similar to the technologies used in the ReWalk exoskeleton system for individuals with spinal cord injury (SCI).

"Utilization of the technology in an IRB approved research study, ahead of our clinical trials planned for next year, is a key milestone in the larger effort to pursue regulatory approval and eventually offer a commercial product to millions of patients who need ambulatory assistance," said ReWalk CEO Larry Jasinski. "We continue to work in earnest on rigorous testing and design modification to develop the best technology for disabled individuals."

Munnybunny
Forum actieveling
Forum actieveling
Berichten: 935
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 386
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 24 Okt 2017 09:37

The Bionic Woman: Paralysed fundraiser triumphs in 10-mile challenge

https://www.metro.news/the-bionic-woman ... ge/792503/

Published October 23, 2017

A FUNDRAISER paralysed from the chest down has completed her ‘toughest challenge to date’ as she walked the 10-mile Great South Run in 24 hours with the help of a bionic suit.

Claire Lomas, who broke her back in a horse-riding accident in 2007, has raised over £575,000 for charity through a number of gruelling endurance events, and became the first person to complete a marathon in her revolutionary Rewalk Suit — a robotic exoskeleton which enables her to walk.

In her latest challenge, Ms Lomas continued throughout the day and night without sleep to walk the race in Portsmouth with the aid of the suit and a pair of crutches.

She was met with cheers and applause as she crossed the line, having posted regular updates on Twitter as she battled wind and rain.

Ms Lomas said she was overwhelmed with emotion as she crossed the finish line, to be met by her two daughters Maisie, five, and Chloe, nine months.

She said the fact this was her first long-distance race without stopping meant ‘it was a little bit unknown’ whether she could finish, and added that she was ‘really grateful to everyone that supported me…. I had a few tears.’

‘I’m tired but I’m still buzzing from the support. Hopefully, I’ll get a good night’s sleep,’ she said as she rested following the event.

At the half way stage, Ms Lomas, from Eye Kettleby, near Melton Mowbray, showed she was keeping in high spirits as she posted a video of herself singing Bon Jovi’s Livin’ On A Prayer.

And she revealed the exhausting effects of the race with a mile to go when she tweeted: ‘Help me get to last mile as sooo tired.’

Her effort has so far raised more than £4,000 for the Nicholls Spinal Injury Foundation.

Ms Lomas, 37, collected an MBE from the Duke of Cambridge earlier in February, just weeks after giving birth to her second daughter.

After collecting her award at the time, she said: ‘My accident was 10 years ago in May.

‘When I think back to that first year or two I would have loved for someone to tell me what the future had in store — back then, everything felt so bleak with so many dark days.

‘I forced myself to take small opportunities and it has led on to bigger things. It has taken a lot of small little steps to get here.’

Munnybunny
Forum actieveling
Forum actieveling
Berichten: 935
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 386
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 02 Nov 2017 14:21

ReWalk beats by $0.13, beats on revs (1.40)

Reports Q3 (Sep) loss of $0.22 per share, excluding non-recurring items, $0.13 better than the Capital IQ Consensus of ($0.35); revenues rose 21.4% year/year to $1.7 mln vs the $1.63 mln Capital IQ Consensus.
16 ReWalk units were placed during the third quarter, compared with 23 ReWalk systems placed in the prior year period, of which 10 were placed in the U.S., three in Europe, and three with distributors. An additional 8 rental units from previous periods converted to purchases. For the first three quarters of 2017, a total of 19 rental units converted to sales. Gross margin improved to 41% during the third quarter of 2017 compared to 21% in the prior year period, primarily attributable to sales mix, an increase in the conversion of rental units to purchases, and lower product costs.

Munnybunny
Forum actieveling
Forum actieveling
Berichten: 935
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 386
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 02 Nov 2017 14:22

ReWalk announces that Germany's national social accident agrees to provide personal exoskeletons to qualifying beneficiaries

Additionally, DGUV recently signed a confirmation letter stipulating that DGUV's member payers, including the health insurance association Berufsgenossenschaft (also known as BG) and state insurers, will approve the supply of exoskeleton systems for qualifying beneficiaries on a case-by-case basis. The growing number of system rentals, along with the recent coverage confirmation from DGUV, reflects broader adoption of the procurement process by DGUV member payers across Germany.

Munnybunny
Forum actieveling
Forum actieveling
Berichten: 935
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 386
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 02 Nov 2017 14:24

ReWalk Robotics Reports Third Quarter 2017 Financial Results
By GlobeNewswire, November 02, 2017, 06:55:00 AM EDT
Vote upAAA



-- 24% YOY growth in Q3 revenue to $1.7 million --

-- Coverage allowed by DGUV and Barmer in Germany of ReWalk personal devices --

YOKNEAM ILIT, Israel and MARLBOROUGH, Mass., Nov. 02, 2017 (GLOBE NEWSWIRE) -- ReWalk Robotics Ltd. (Nasdaq:RWLK) ("ReWalk" or "the Company") today announced its financial results for the three- and nine-month periods ended September 30, 2017.

Highlights of and subsequent to the third quarter include:

Revenues grew 24% to $1.7 million and 46% to $6.2 million for the three and nine months ended September 30, 2017, respectively, compared to revenues of $1.4 million and $4.3 million for the three- and nine-months ended September 30, 2016, respectively;



Placed 16 and 84 units during the three and nine months ended September 30, 2017, respectively, compared to 23 and 80 units during the three and nine months ended September 30, 2016, respectively. An additional eight previously rented units converted to sales during the quarter;



Secured seven favorable commercial insurance coverage decisions;



Increased pending insurance claims to 218 in the U.S. and Germany, as of September 30, 2017, compared to 149 as of the end of the prior year period;



Positive reimbursement determinations made in Germany by DGUV, a social accident insurance provider, and Barmer, a national social health insurance provider, for the ReWalk Personal device, to provide insurance coverage on a case-by-case basis to all qualifying beneficiaries; and



Completed critical design review processes and began the pre-clinical testing of the Restore lightweight soft-exosuit base design in preparation for a prospective clinical study and eventual commercialization of an initial indication designed for stroke patients.
"Our business continues to deliver year over year growth as we focus on advancing our key initiatives including insurance reimbursement coverage for the ReWalk Personal device and progressing our innovative soft suit exoskeleton technology, the Restore, designed for individuals who experienced a stroke. We view the Restore system as a platform technology which we believe has significant applications beyond stroke in potentially treating multiple sclerosis, Parkinson's disease, and other lower limb disabilities," stated Larry Jasinski, Chief Executive Officer.

"We have begun pre-clinical testing of the Restore system to study its safety and use in the rehabilitation setting for the mobility needs of stroke patients. We are targeting a clinical trial with the Restore system to begin in early 2018 and aim to commercialize the system for use by stroke patients in Europe in late 2018, followed by the United States in late 2018 or early 2019, subject to the timing and receipt of CE mark and Food and Drug Administration clearance," he added.

Third Quarter 2017 Financial Results

Total revenue was $1.7 million for the third quarter of 2017, an increase of 24% compared with $1.4 million in the third quarter of 2016. 16 ReWalk units were placed during the third quarter, compared with 23 ReWalk systems placed in the prior year period, of which 10 were placed in the U.S., three in Europe, and three with distributors. An additional 8 rental units from previous periods converted to purchases. For the first three quarters of 2017, a total of 19 rental units converted to sales.

Gross margin improved to 41% during the third quarter of 2017 compared to 21% in the prior year period, primarily attributable to sales mix, an increase in the conversion of rental units to purchases, and lower product costs.

Total operating expenses in the third quarter of 2017 were $6.1 million compared with $7.7 million in the third quarter of 2016. Operating expenses in the third quarter of 2017 reflect initiatives to reduce spending announced earlier in 2017.

Net loss was $5.8 million for the third quarter of 2017 compared with a net loss of $7.9 million in the prior year quarter. Non-GAAP net loss for the third quarter was $4.8 million compared with a non-GAAP net loss of $6.7 million in the third quarter of 2016.*

*A reconciliation of net loss to non-GAAP net loss is included at the end of this press release.

Liquidity

ReWalk ended the third quarter of 2017 with $12.9 million in cash and cash equivalents.

Conference Call

ReWalk management will host its third quarter conference call as follows:

Date November 2, 2017
Time 8:30 AM EDT
Telephone U.S: (844) 423-9889
International: (716) 247-5804
Israel: 18 09 45 78 77
Access code: 4999768
Webcast (live and archive) http://www.rewalk.com under the "Investors" section.
A telephone replay will be available shortly after the completion of the call for two weeks at (855) 859-2056 (U.S.) or (404) 537-3406 (International). The passcode for the replay is 4999768.

Munnybunny
Forum actieveling
Forum actieveling
Berichten: 935
Lid geworden op: 17 Sep 2014 14:20
waarderingen: 386
Contact:

Re: Rewalk Robotics

Berichtdoor Munnybunny » 06 Nov 2017 13:10

Met $5 zou ik al hééél tevreden zijn.

ReWalk Robotics Ltd (NASDAQ:RWLK) had its target price trimmed by Jefferies Group LLC from $8.00 to $5.00 in a research note issued to investors on Friday morning. The firm currently has a buy rating on the medical device company’s stock.